BACKGROUND
An exacerbation of COPD is defined as an acute worsening of respiratory symptoms that result in additional therapy. COPD is currently the fourth leading cause of death in the world. There is a need for prospective trials in COPD based on hard clinical outcomes such as death to bring improvements in clinical management.

COPD is a costly disease with both direct costs (value of health care resource devoted to diagnosis and management) and indirect costs (monetary consequences of disability, missed work, premature mortality and caregiver or family costs resulting from the illness). Diagnosis tests for COPD is spirometry FEV1/FVC. Spirometry is costly and is not readily available in rural settings and the technique to perform spirometry involves a lot of patient’s conscious effort. Whereas ECG is easily available, affordable, does not require patient's conscious effort. We wanted to predict the electrocardiographic findings predicting mortality in acute exacerbation of COPD.

METHODS
This is an observational study including 101 patients with COPD acute exacerbations admitted in our institution for a period of 1 year. Selected patients were evaluated with a detailed clinical history and a 12 lead ECG is taken. Data was collected and tabulated. Statistical analysis was done using SPSS Software Version 12.0 and Epi Info Version 3.4.1. Univariate analysis comparing various variables in survivors and non survivors was done using Chi Square test and p value and Odds ratio were calculated. Then multivariate analysis was done using linear regression analysis to find out the most important independent predictors of mortality in COPD acute exacerbations. Study was approved by institutional ethics committee.

RESULTS
In this study, all the patients were males. 34 patients died during treatment. In the study, mean age of patients was 62.33 years. Of the patients who died, 10 (29.41%) were beedi smokers, and 24 patients were cigarette smokers. More patients belonged to the group with heavy smoking score, i.e.; >400. Presence of p pulmonale and RVH in ECG was found to be a predictor of poor outcome in case of a COPD acute exacerbation (p value <0.05).

CONCLUSIONS
In this study, majority of the patients belonged to the age group 60-70 years. Dyspnoea was the predominant symptom of our patients. Mortality rate of COPD acute exacerbations was 33.66% in this observational study. Electrocardiographic findings of p pulmonale and right ventricular hypertrophy were found to be predictors of mortality in COPD acute exacerbations by univariate analysis and multivariate analysis. In this study, electrocardiographic findings of p pulmonale and right ventricular hypertrophy were found to be important predictors of mortality in COPD acute exacerbations.

KEY WORDS
COPD Exacerbations, Mortality, ECG Findings

Among patients with an acute exacerbation of COPD and a PaCO2 of 50 mmHg or more, the six and 12-month mortality rates are approximately 33 and 43 percent, respectively. It is estimated that 14 percent of patients admitted for an exacerbation of COPD will die within three months of admission. Survival time was independently related to severity of illness, body mass index (BMI), age, prior functional status, PaO2/FiO2, congestive heart failure, serum albumin, and the presence of cor-pulmonale.

COPD is a costly disease with both direct costs (Value of health care resource devoted to diagnosis and management) and indirect costs (Monetary consequences of disability, missed work, premature mortality and caregiver or family costs resulting from the illness). Diagnostics test for COPD is spirometry FEV1/FVC. Spirometry is costly and is not readily available in rural settings and technique to perform spirometry involves a lot of patient’s conscious effort. Whereas ECG is easily available, affordable, does not require patient’s conscious effort.

A complex and interrelated set of risk factors influences functional decline, exacerbation and early mortality in patients with COPD. With limited health care resources, efficient and effective management of COPD ideally involves identifying and focusing efforts on individuals who are at particular risk.

There is a need for prospective trials in COPD based on hard clinical outcomes such as death to bring improvements in clinical managements. Better understanding of COPD is imperative. This potentially disabling and fatal disease is already epidemic in many countries and appears destined to become worldwide in coming decades given trends of smoking prevalence.

COPD develops insidiously. However, the disease can be easily detected with simple spirometric testing before symptoms occur, and cessation of smoking can slow or even halt the disease progression and prolong survival. Once the disease is symptomatic, a coordinated, comprehensive, and individualized approach to treatment, both pharmacologic and non-pharmacologic, can increase functional status, prevent complications, and improve the quality of life.

Exacerbations of COPD can range from those that are nuisances to those that are life threatening, but treatment can shorten the duration of illness and improve outcomes. In advanced disease, treatments including surgical approaches are directed toward relief of symptoms and prolongation of survival. Thus, although there is certainly need for improvement in our treatment of symptomatic COPD, current treatments are effective and a nihilistic attitude is not warranted. Mortality rate, the possible factors affecting mortality and intubation in patients with acute exacerbation of chronic obstructive pulmonary diseases (COPD) are yet unclear. So, this study intended to find out the mortality rate in patients with COPD acute exacerbations and also to find out simple clinical and laboratory parameters that may predict the mortality. After COPD becomes clinically apparent, the median survival is about 10 years. Several factors have been identified that predict poor survival in COPD. These include low FEV1, active smoking status, hypoxemia, poor nutrition, the presence of cor-pulmonale, resting tachycardia, low exercise capacity, severe dyspnoea, poor health-related quality of life, anemia, frequent exacerbations, co-morbid illnesses, and low carbon monoxide diffusing capacity. Patients with an FEV1 less than 35 percent predicted have about 10 percent mortality per year. If a patient reports that they are unable to walk 100 meters without stopping because of breathlessness, the 5-year survival is only 30 percent.

**Aim of the Study**

To evaluate the electrocardiographic findings predicting mortality in acute exacerbation of COPD.

**METHODS**

This study was an observational study. Patients admitted to Institute of chest diseases, Medical College Calicut with signs and symptoms of chronic obstructive pulmonary disease acute exacerbation were included in the study. Study period was 1 year.

**Inclusion Criteria**

All cases of COPD diagnosed by clinical features and spirometry criteria as per GOLD 2006 and is on treatment for more than one year, now admitted in our institution with exacerbation were included in the study.

**Exclusion Criteria**

Patients with co-morbid conditions like
- Primary heart Disease.
- Cirrhosis Liver.
- Immunodeficiency.
- Renal failure.

**Method of Data Collection**

Patients enrolled in to the study were evaluated in detail by collecting the following:

I. A detailed history including
   1. Age.
   2. Sex.
   3. Smoking history.
   4. Occupation.
   5. Previous history of hospitalization during last 1 year.
   6. Previous history of intubations.

II. Electrocardiography

12-lead ECG of the selected patients were taken. Patients with ECG findings of either P wave amplitude >2.5 mm or peaked P wave were considered as criteria for P pulmonale. RVH is defined by one or more of the following criteria:
- Right axis deviation ≥110°
- R/S ratio in V1 > 1
- R wave in V1 ≥ 7 mm
- S wave in V1 < 2 mm
- QR pattern in V1
- R wave in V1 + S wave in V5 or V6 > 10.5 mm
- R/S ratio in V5 or V6 ≤ 1
- Onset of intrinsicsid deflection in V1 = 0.035 – 0.055
- Second rSR’ in V1 with R’ ≥ 10 mm
RESULTS
In this study conducted a brief idea about the mortality rate in COPD acute exacerbation and effect of ECG findings on the mortality of COPD during its exacerbation is given.

Graph 1
In this observational study 101 patients admitted with COPD acute exacerbations were considered. All the patients were males. Death was considered as poor outcome. 34 patients died during treatment (Graph 1).

Graph 2
In the study mean age of patients was 62.33 years and most of the patients belong to the age group between 60 – 70 years (Graph 2).

Graph 3
Majority (58 patients) had MMRC grade 4 dysnea at presentation (Graph 3).

Graph 4

Graph 5

Graph 6

Graph 7

Table 1

<table>
<thead>
<tr>
<th>Variable</th>
<th>Correlation Coefficient</th>
<th>Std. Error</th>
<th>F-Test</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ECG Pulmonale</td>
<td>-0.227</td>
<td>0.078</td>
<td>8.3947</td>
<td>0.004692</td>
</tr>
<tr>
<td>ECG RVH</td>
<td>-0.227</td>
<td>0.088</td>
<td>9.51948</td>
<td>0.004652</td>
</tr>
<tr>
<td>Constant</td>
<td>0.373</td>
<td>0.512</td>
<td>0.5296</td>
<td>0.468610</td>
</tr>
</tbody>
</table>

Table 3
Correlation Coefficient: $r^2 = 0.43$
By multivariate analysis also ECG changes of p pulmonale and right ventricular hypertrophy were found to be independent predictors of mortality in patients with COPD acute exacerbations (p value<0.05). Table 3

ECG showed features of p pulmonale in 50 patients and features of RVH in 33 patients. 26 and 27 patients who died had features of p pulmonale and RVH in their ECG respectively (Graph 7). Presence of p pulmonale and RVH in ECG was found to be a predictor of poor outcome in case of a COPD acute exacerbation (p value<0.05) (Table 1 and 2).

100% of patients were smokers. 59.4% were smoking cigarettes (Graph 4). Of the patients who died 10 (29.41%) had beedi smokers and 24 patients were cigarette smokers. More number of patients belonged to the group with heavy smoking score, i.e.; >400 (graph 5). 21 patients were still smoking at presentation (Graph 6).

Statistical Analysis

Data were collected and tabulated. Statistical analysis was done using SPSS Software version 12.0 and Epi Info version 3.4.1. Univariate analysis comparing various variables in survivors and non survivors was done using Chi Square test and p value and Odds ratio were calculated. Then multivariate analysis was done using linear regression analysis to find out the most important independent predictors of mortality in COPD acute exacerbations.

Study was approved by institutional ethics committee.

DISCUSSION

In this study 101 patients admitted with COPD acute exacerbations were taken into consideration. All the patients were males. Death was considered as the poor outcome. We tried to find out important predictors of mortality in patients during COPD acute exacerbations. 34 (33.66%) patients died during treatment and 67 (66.34%) survived the acute event. 3 patients were mechanically ventilated. All the three patients expired. Ucuqin et al found out a similar in hospital mortality rate (33.1%) for patients admitted with COPD acute hypercapnic respiratory failure in their study. Susheel Patlet al mentioned in their study that previous studies of selected populations of patients with COPD have estimated in-hospital mortality to range from 4% to 30%.

Demographics

In our study mean age was 62.33 and most of the patients belonged to the age group between 50 – 60 years. Divay Chandra et al found almost similar age group of patients to be predominant symptom of our patients. Mortality rate of COPD acute exacerbations was 33.66% in this observational study. Electrocardiographic findings of p pulmonale and right ventricular hypertrophy were found to be predictors of mortality in COPD acute exacerbations by univariate analysis and multivariate analysis.

Electrographic Findings

26 (76.5%) of 34 patients who died had features of corpus pulmonale in ECG and 27 (79.4%) had features of right ventricular hypertrophy. Presence of these ECG findings were an important predictor of mortality in COPD exacerbations as evidenced by statistical analysis (p =0.000) table 3 and 4. Raffaele Antonelli Incalzi et al found out that the Cox regression analysis identified S2S3S pattern, right atrial overload (RAO), and alveolar-arterial oxygen gradient (PAO2: PaO2) >48 mmHg during oxygen therapy as the strongest predictors of death. Limitations of this study are the following; first, lack of right heart catheterization in most of our patients prevented us from assessing the relationship between ECG signs of CCP and pulmonary hypertension; second, ECG signs of CCP coexisted in a large fraction of patients, which is expected to weaken the prognostic meaning of individual ECG signs; and third, the diagnosis of coronary artery disease based on ECG criteria might be unreliable in some CCP patients.

L. Fuso et al observed that selected co-morbid diseases and electrocardiographic signs of right ventricular hypertrophy play a major prognostic role in advanced chronic obstructive pulmonary disease. The present data were derived from patients with severe COPD and thus cannot be applied to the overall population of COPD patients. Efforts should be made to further characterize the spectrum of co-morbid diseases and to assess their prognostic role in the earlier stages of chronic obstructive pulmonary disease. The physio pathological and clinical bases of the relationship between electrocardiogram signs of right ventricular hypertrophy and death should be clarified. The prevalent type of respiratory disease, i.e. bronchitic or emphysematous, should also be identified, because it might have prognostic relevance. The clinical assessment of patients with chronic obstructive pulmonary diseases should include these easily measurable variables. Ram Abhishek Sharma et al concluded that if P pulmonale is present Chronic obstructive pulmonary disease is severe and patient may be managed accordingly even if spirometry is not available. If P pulmonale is present it can be concluded that COPD is severe, and patient may be managed accordingly even if spirometry is not available. If P pulmonale is present, patients may be started on both inhaled corticosteroids as well as on inhaled long acting β2 agonist. In many hospitals in India ECG facilities are available but spirometry is not available, especially in rural areas which contribute a large portion of population in India. ECG does not require cooperation from patient, unlike spirometry. In India it is often difficult for patients to understand how to perform spirometry. Even after repeated attempts they are not able to do it and this can lead to wrong diagnosis.

CONCLUSION

In this study, majority of the patients belonged to the age group 60-70 years. Dyspnoea was the predominant symptom of our patients. Mortality rate of COPD acute exacerbations was 33.66% in this observational study. Electrocardiographic findings of p pulmonale and right ventricular hypertrophy were found to be predictors of mortality in COPD acute exacerbations by univariate analysis and multivariate analysis.
REFERENCES


